Zimmer Biomet
About: Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Employees: 18,000
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
69% more first-time investments, than exits
New positions opened: 144 | Existing positions closed: 85
50% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 9 (+3) [Q4]
4% more funds holding
Funds holding: 964 [Q3] → 1,002 (+38) [Q4]
2.16% more ownership
Funds ownership: 89.19% [Q3] → 91.35% (+2.16%) [Q4]
2% less capital invested
Capital invested by funds: $19.6B [Q3] → $19.2B (-$377M) [Q4]
20% less repeat investments, than reductions
Existing positions increased: 297 | Existing positions reduced: 369
26% less call options, than puts
Call options by funds: $62.5M | Put options by funds: $84M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$112
0%
upside
Avg. target
$125
11%
upside
High target
$140
25%
upside
6 analyst ratings
4 positive
67%
1 neutral
17%
1 negative
17%
Truist Securities Richard Newitter 51% 1-year accuracy 22 / 43 met price target | 1%upside $113 | Hold Reiterated | 10 Feb 2025 |
Barclays Matt Miksic 59% 1-year accuracy 24 / 41 met price target | 0%downside $112 | Underweight Maintained | 10 Feb 2025 |
RBC Capital Shagun Singh 55% 1-year accuracy 37 / 67 met price target | 11%upside $125 | Outperform Maintained | 7 Feb 2025 |
Raymond James Jayson Bedford 56% 1-year accuracy 14 / 25 met price target | 6%upside $119 | Outperform Maintained | 7 Feb 2025 |
JMP Securities Andrew Boone 43% 1-year accuracy 40 / 93 met price target | 25%upside $140 | Market Outperform Reiterated | 7 Feb 2025 |
Financial journalist opinion
Based on 10 articles about ZBH published over the past 30 days
Neutral
PRNewsWire
8 hours ago
Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System
Expanding Thoracic Portfolio WARSAW, Ind., and ZUG, Switzerland , April 1, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announced its RibFix Advantage® Fixation System has received CE Mark certification – the first CE Mark for an intrathoracic rib fixation system.
Negative
Investors Business Daily
5 days ago
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.
Positive
Zacks Investment Research
6 days ago
3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025
Investing in surgical robotics stocks like ISRG, ZBH and STXS can be profitable for investors in 2025.
Neutral
Zacks Investment Research
1 week ago
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
Zimmer Biomet's robust Knee business appears promising. However, a dull macroeconomic condition adds to the worry.
Negative
Zacks Investment Research
2 weeks ago
Zimmer Biomet Focuses on Innovation Amid Growing Competition
Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.
Positive
Zacks Investment Research
2 weeks ago
ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
Neutral
Business Wire
3 weeks ago
Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE: ZBH) (“Zimmer Biomet”). The expiration of the waiting period under the.
Neutral
PRNewsWire
3 weeks ago
Zimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting
Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona® Revision SoluTion™ Femur, and Debut of ZBX™ Ambulatory Surgery Center Solutions WARSAW, Ind., March 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio of orthopedic and musculoskeletal innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting being held March 10-14 in San Diego.
Neutral
PRNewsWire
3 weeks ago
Zimmer Biomet Receives FDA Clearance for Persona® Revision SoluTion™ Femur
A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona® Revision SoluTion™ Femur, a revision knee implant component offering an alternative for patients with sensitivities to certain metals.
Neutral
PRNewsWire
3 weeks ago
Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer
WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer.
Charts implemented using Lightweight Charts™